Since KLF10 targets the promoter region of EGFR and inhibits EGFR transcription, we speculate that KLF10 might play a role in the synergetic anti-tumor effects of PDT/gemcitabine combination through inhibiting EGFR. This evidence concerns the gene EGFR and neoplasm.